Mycophenolate mofetil (MMF), a morpholinoethyl ester of mycophenolic acid (MPA), is currently widely used in organ transplantation as an immunosuppressant to prevent acute and chronic rejection.
In immunosuppressive therapy after organ transplantation, therapeutic drug monitoring (TDM) of a calcineurin inhibitor, tacrolimus (FK) or cyclosporine A (CyA) is always needed, because of its narrow therapeutic range of blood concentration and various pharmacokinetic properties. However, a routine TDM for MPA after MMF dosing has not been recommended and empiric dosing was a common regimen for many institutions.
Several studies concerning the relationship between MPA pharmacokinetics and clinical outcome have been performed in renal transplant patients. [5] [6] [7] [8] [9] These reports suggest that patients with low MPA AUC appeared to be at high risk for graft rejection. In Japanease renal transplant patients, Takahashi et al. reported an association between MPA AUC and the risk for acute rejection in a retrospective analysis of pharmacokinetic data. 10) Recently, Okamoto, a coauthor of this article, reported a relationship between the pharmacokinetic characteristics of MPA, such as AUC MPA 0-9 , and acute rejection or the development of side effects, as observed at our institution.
11) However, no reports have been published concerning the relationship between MPA pharmacokinetics and clinical outcome and the development of side effects in other Japanese renal transplant patients, to the best of our knowledge.
On the other hand, many reports have examined the effects of concomitant immunosuppressants such as CyA or FK on MPA pharmacokinetics. [12] [13] [14] [15] [16] However, most of these reports concluded that further studies are needed to fully understand the effect of FK or CyA on MPA pharmacokinetics. In addition, such drug interaction has not been reported in Japanese transplant patients.
In this study, to obtain more useful information for TDM of MPA after MMF dosing in Japanese renal transplant patients, the association between MPA pharmacokinetic characteristics and the development of side effects was investigated in detail. Moreover, the effect of other concomitant immunosupressants on MPA pharmacokinetics was also investigated.
On the other hand, secondary elevation of MPA plasma level derived from enterohepatic recirculation (EHRA) has been reported [17] [18] [19] and this was also observed in our institution. There is a possibility that EHRA increases the exposure of drug to the intestine and elevates the trough plasma concentration of drugs during repeated administration. In addition, reduction or induction of EHRA by concomitant drug use may be a cause of drug interaction. Therefore, in this study, variations of the secondary elevation of MPA plasma level as an index of EHRA, and the effects of EHRA on pharmacokinetic characteristics of MPA and the development of side effects were also investigated.
MATERIALS AND METHODS

Immunosuppressive Regimen
The immunosuppressive regimen using MMF developed by the department of transplantation and regenerative surgery, Kyoto Prefectural University of Medicine, is described below.
For living-related renal transplantation, the initial dose of FK (0.3 mg/kg/d, PO, BID (bis in die)) or CyA (12 mg/kg/d, PO, BID) was administered orally for 2 d before transplantation. FK (0.1 mg/kg/d) or CyA (4 mg/kg/d) was administered by continuous intravenous infusion on the day of transplantation, followed by FK (0.3 mg/d/kg, PO, BID) or CyA (12 mg/d/kg, PO, BID) of oral administration for 3 weeks. The dose of FK or CyA was adjusted based on the results of the blood trough level. On day 2 after transplantation, mycophenolate mofetil (20 to 25 mg/kg/d, PO, BID) was added to the regimen. A dose of 500 mg of methylprednisolone was given on the day of transplantation, followed by 50 mg/d of PSL (PO, BID) on days 0 to 3. Then, 40 mg/d of PSL (PO, BID) was administered orally on days 4 to 11. After that, PSL was reduced each week from 30, 25, 20, 15 to 10 mg/d (PO, BID).
Pharmacokinetic Studies of MPA, FK and CyA For this study, a total of 160 observed pharmacokinetic parameters such as AUC, C max , T max and trough blood level from 63 recent living-related renal transplant patients (male, 41; female, 22; age, 7-69 years), operated on in Kyoto Prefectural University of Medicine, were collected retrospectively.
To obtain the pharmacokinetic parameter, i.e. AUC, pharmacokinetic studies of MPA, FK or CyA were performed on days 7, 14, 21 or 28 after transplantation. Blood samples were obtained at times 0, 1, 2, 3, 4, 6 and 9 h after drug administration. Pharmacokinetic parameters, such as AUC 0-9 (AUC MPA 0-9 , AUC FK 0-9 , AUC CyA 0-9
), C max and T max for MPA were obtained from these data. Samples for each trough blood (CyA, FK) or plasma (MPA) level was obtained at 15 h after MMF dosing. In order to obtain the useful information of MPA TDM, the relationship between each parameter was investigated in detail.
Blood concentration of CyA was measured by fluorescence polarization immunoassay using an Abotto TDX ® system. Blood concentration of FK was measured by microparticle enzyme immunoassay using the Abotto IMX ® system. Plasma concentration of MPA was measured by enzymemultiplied immunoassay technique using the Dimension ® clinical chemistry system (DADE BEHRING). AUC MPA 0-9 , AUC FK 0-9 and AUC CyA 0-9 were calculated by the trapezoidal rule. C max and T max for MPA were of actual value.
Pharmacokinetic Study of PSL Subjects who participated in this study were 20 recent patients (male, 11; female, 9; age, 11-66 years) within the population of pharmacokinetic study of MPA, FK, CyA as described above. The plasma PSL concentration was measured using high-performance liquid chromatography (HPLC) method previously reported. 20) The standard curves of PSL were linear over the range of 0.01-500 mg/ml. The C.V. values (%) of inter-and intra-assay reproducibilities were under 10%. Pharmacokinetic study of PSL was performed on day 7. Plasma samples for the determination of the PSL concentration were collected at the steady state before the oral dose of 40 mg/d on days 4-11 after transplantation (after 15 h PSL dosing). The mean PSL concentration of 3 samples (40 mg/d of PSL dose at steady state) obtained in each patient was as for the PSL trough level (TL PSL40 ). To obtain the pharmacokinetic parameter, AUC, multiple blood samplings were performed in the same way as described above on day 7 (40 mg/d of the PSL dose at the steady state) after transplantation (AUC 0-9 PSL40 ). These parameters have been used for the estimation of FK or CyA trough blood levels in our laboratory. 20) Then, the relationship between the pharmacokinetic characteristics of MPA after oral medication of MMF and that of PSL was investigated.
Relationship between the Pharmacokinetic Characteristics of MPA after Oral Medication of MMF and the Development of Side Effects Such as Leukopenia and Diarrhea On the 153 observed pharmacokinetic parameters such as AUC MPA 0-9 , C max , T max , TL MPA , and dose for MPA from 63 patients until 4 weeks after transplantation, we compared leukopenia (nϭ9) or diarrhea (nϭ26) cases with the other cases (nϭ144 or nϭ127, respectively). According to the normal value of WBC in our institution (Ͼ3800), we defined WBC Ͻ3800 as leukopenia. In addition, in general, the normal number of dejection is once or twice a day, therefore, we define the number of dejection Ͼ3 times a day as diarrhea. Moreover, the development of leukopenia and diarrhea in the EHRA observed group (EHRA group; defined as when the plasma level of MPA at 9 h, after dosing was higher than that at 6 h after dosing, C 6 ϽC 9 ) was compared with that in the non-EHRA group (C 6 ϾC 9 ).
Relationship between the Pharmacokinetic Characteristics of MPA after Oral Medication of MMF and That of CyA or FK The pharmacokinetic characteristics of MPA after MMF (1000 or 1500 mg/d) medication with FK were compared with that after MMF (1000 or 1500 mg/d) medication with CyA. In addition, the relationship between the pharmacokinetic characteristics of MPA and that of FK or CyA (AUC [0] [1] [2] [3] [4] [5] [6] [7] [8] [9] , C max , T max and the blood trough level; TL) were investigated. Moreover, for each case (FK or CyA), the number of EHRA cases was compared with the number of non-EHRA cases, and the relationship between the EHRA group and the non-EHRA group on pharmacokinetic characteristics of FK or CyA were also investigated.
Effect of the Pharmacokinetic Characteristics of MPA after Oral Medication of MMF on Biochemical Parameters Such as TP, ALB, and T-Bil
Regarding the 52 (1000 mg/d MMF) or 59 (1500 mg/d MMF) observed pharmacokinetic parameters of MPA such as AUC MPA 0-9 , C max , T max , and TL MPA until 4 weeks after transplantation, the relationships between these parameters and biochemical parameters such as TP, ALB and T-Bil were investigated. The range of these parameters were not wide enough to investigate a correlation with pharmacokinetic parameters, therefore, observed data was divided into 2 groups in each biochemical parameter; (i) low; 2.8-3.7, high; 3.8-4.5 (g/dl) for ALB, (ii) low; 4.8-5.9 high; 6.0-7.4 (g/dl) for TP, (iii) low; 0.32-0.64 high; 0.65-3.61 (mg/dl) for T-Bil, and the differences of the pharmacokinetic parameters between the low and high groups was investigated. Moreover, correlation between the values of pharmacokinetic parameters and biochemical parameters was investigated. Association between various parameters was measured by Pearson's correlation coefficients after checking the normal distribution in each pa-rameter. In addition, the difference of each biochemical parameter between the EHRA group and the non-EHRA group were also investigated by Student's t-test after testing the homoscedasticity by F-test.
The study was approved by the Ethics Committee of Kyoto Prefectural University of Medicine. Table 1 shows the pharmacokinetic characteristics of MPA after oral administration of MMF. Changes of AUC MPA 0-9 , C max and TL MPA were not observed at doses of 750-1500 mg a day. T max had no variation. In cases with under 500 mg dose/d, AUC was obviously low, although there were not many patients in this group. Table 2 shows the pharmacokinetic characteristics of MPA after oral administration of MMF at doses of 1000 or 1500 mg/d, for which we obtained data at 2 and 4 weeks after transplantation. Significant differences were not observed between the 2 different dose groups and between 2 different POD (postoperation days) groups for any parameters.
RESULTS
However, in seven patients that the pharmacokinetic parameters could be obtained after leaving the hospital (postoperation days, POD; 67-483), increase of AUC was observed (compared with on day 28, 124-268%), even though the same dose of MMF had been administered.
In a total of 160 observed pharmacokinetic parameters from 63 renal transplant patients (on day 14; nϭ53, on day 28; nϭ50), correlation coefficients between AUC MPA 0-9 and C max , T max , TL MPA , dose of MMF or dose of MMF per body weight are shown in Table 3 . In all cases, AUC MPA 0-9 correlated well with C max or TL MPA (rϭ0.815-0.769, 0.793-0.722). However, AUC MPA 0-9 was not correlated with T max , dose of MMF, or dose of MMF per body weight. Table 4 shows the pharmacokinetic characteristics of MPA with or without the typical side effects, leukopenia and diarrhea (nϭ153). No significant differences were observed for each parameter. However, interestingly, the rate of the development of both leukopenia and diarrhea in the EHRA group was 2 times higher than that in the non-EHRA group (Table  5) .
On day 14, AUC MPA 0-9 and TL MPA at a dose of 1500 mg/d with the FK-treated group was significantly higher than that with the CyA-treated group as shown in Table 6a . In patients treated with 1000 mg/d MMF, TL MPA of the FK-treated group was also significantly higher than that with the CyA-treated group, and although not significant, AUC MPA 0-9 for the FKtreated group was higher than that of the CyA-treated group. Moreover, on day 28, AUC MPA 0-9 and TL MPA at a dose of 1500 mg/d with the FK-treated group was significantly higher than that with CyA-treated group, and although not significantly, AUC MPA 0-9 at a dose of 1000 mg/d with the FKtreated group was higher than that with CyA-treated group as shown in Table 6b . (Table 8a) , although, in the case of FK medication, a significant difference was not observed on AUC FK 0-9 between the EHRA and non-EHRA group (Table  8b) .
Correlation of pharmacokinetic characteristics of PSL (AUC 0-9 PSL40 , TL PSL40 ) and those of MPA (AUC MPA 0-9 , C max , T max or TL MPA ) on days 14 or 28 was investigated. TL PSL40 and AUC 0-9 PSL40 varied from 20.5 to 283.7 ng/ml and from 247.5 to 4397.3 ng · h/ml, respectively. On day 14, a weak negative correlation was observed between AUC 0-9 PSL40 and TL MPA (rϭϪ0.340), although no correlations were observed between the other parameters. On day 28, correlations were not observed between each parameter. Table 9 shows the differences of pharmacokinetic parameters of MPA between low and high ALB, TP or T-Bil groups at MMF doses of 1000 or 1500 mg/d. In both MMF doses of 1000 and 1500 mg/d, AUC MPA 0-9 and TL MPA in the high ALB group were significantly higher than in the ALB low group. In addition, AUC MPA 0-9 and TL MPA in the low T-Bil group were higher than that in the T-Bil high group, though statistical significance was not observed. On the other hand, no difference on any pharmacokinetic parameters of MPA was observed between the TP high group and TP low group. Moreover, correlation between the values of pharmacokinetic parameters and such biochemical parameters were investigated. A positive correlation was observed between ALB and AUC MPA 0-9 (rϭ0.425) or TL MPA (rϭ0.406), and weak negative correlation was observed between T-Bil and TL MPA (rϭϪ0.306). In addition, T-Bil level in the RA group was significantly lower than in the non-RA group as shown in Table 10 . 
DISCUSSION
In renal transplant patients, some studies have been reported on the pharmacokinetic characteristics of MPA after oral administration of MMF such as AUC until 12 h after dosing (AUC MPA 0-12 ), C max and T max . 1, 6, 8, [21] [22] [23] Each parameter at a dose of 1000 or 1500 mg/d was reported for the following values; AUC MPA 0-12 of 13.4-61.3 mg · h/ml, C max of 5.5-32.8 mg/ml, and T max of 1.1-2.6 h. Though the AUC values in this study were measured up to 9 h after MMF dosing, we obtained similar values for AUC, C max and T max , as shown in Table 1 . Recently, Okamoto, a coauthor of this article, reported the relationship between the pharmacokinetic characteristics of MPA such as AUC MPA 0-9 and an acute rejection or the development of the side effect in our institution. 10) His report showed that AUC MPA 0-9 of the acute-rejection-negative group was significantly higher than that of the acute-rejection-positive group, and concluded that the target level of AUC MPA 0-9 should be approximately 30 mg · h/ml using the present immunosuppressive regimen. Our target AUC MPA 0-9 value was based on his report, and the results of this study were well followed (Table 1) .
On the other hand, although MMF dose was varied, changes were not so much observed in each parameter (Table  1) , and differences of each parameter were not observed between 1000 and 1500 mg/d on day 14 and 28 (Table 2) , showing a large variety of pharmacokinetic characteristics of MPA after MMF dosing. In addition, though the systemic exposure is measured as AUC, there were no correlations between AUC MPA 0-9 and dose per body weight, indicating that body weight may not be a useful index of dosing regimen (Table 3) . Increase of AUC (124-268%) after leaving the hospital was observed, although, in inpatients, differences in AUC were not observed between 14 POD and 28 POD (Table  2) . Some investigators have reported that MPA clearance decreases with time. [24] [25] [26] More than 99% of MPA in blood is retained in plasma.
27) The plasma protein binding ratio of MPA and its glucuronide metabolite (MPAG) are 98 to 99%, respectively, 27) and 82% bound to albumin. 28) It has been demonstrared that the decreases in MPA clearance is accounted for by increasing the serum protein-binding ratio because of increasing serum albumin level with the recovery of renal function. 24, 28) Therefore, the observations in this study suggest that the monitoring of AUC MPA after the leaving hospital is necessary.
Major toxic effects of MMF are gastrointestinal toxicity, hematologic toxicity and infections. In this study, no significant differences were observed between the pharmacokinetic characteristics of MPA with and without the side effects such as leukopenia or diarrhea. van Gelder et al. reported that side effects characteristic of MMF appeared to be related to dose but not to MPA plasma concentration, 5) supporting our results in Japanese renal transplant patients. Gastrointestinal toxicity such as diarrhea or abdominal pain were the most common adverse event in our institution. 29) Oellerich et al. also reported that a lack of correlation was observed between the development of gastrointestinal toxicity and plasma level of MPA. 30) Moreover, in this study, a difference was not observed between the development of diarrhea and plasma level of MPA; however, the development of diarrhea in the EHRA group was 2 times higher than that in the non-EHRA group (Table 5) . Therefore, there may be a relationship between direct exposure of MPA to intestinal epithelium and the development of intestinal toxicity. Regarding hematologic toxicity, the possibility that protein-free MPA AUC was a more useful parameter than total MPA AUC as a risk factor for leukopenia was suggested. 31) On the other hand, in this study, the development of leukopenia in an EHRA group was also 2 times higher than that in the non-EHRA group (Table 7) . Therefore, the increase of EHRA may reflect the increase of protein free MPA, because only protein free MPA was conjugated in plasma, leading to increase of MPAG excretion into the bile.
It has been reported that the MPA plasma level of the patients who were treated with FK was higher than that with CyA [12] [13] [14] [15] [16] caused by inhibition of the glucuronidation of MPA. However, in Japanese renal transplant patients, clinical study reports for both increasing MPA plasma level by FK and decreasing that by CyA cannot be found, to the best of our knowledge.
In this study, AUC MPA 0-9 with the FK medication group was significantly higher than that with the CyA medication group. AUC CyA 0-9 and TL CyA were negatively correlated with 33) These data suggest that CyA inhibits MPAG excretion into the bile, leading to MPAG accumulation in the plasma and a reduction of the EHRA of MPA. Therefore, the contribution to the AUC of reabsorbed MPA would be decreased. Kobayashi et al. reported that the reduction of MPAG excretion into bile was caused by inhibition of multidrug resistance-associated protein 2 (MRP2), which plays a primary role in the biliary excretion of glucuronide conjugates of drugs, by CyA in biliary excretion study of MPAG using a hyperbilirubinemic rats (a strain lacking MRP2). 34) In this study, patients with CyA medication included 20.2% of RA cases, whereas patients with FK medication included 37.5% of RA cases, clinically supporting these considerations.
Regarding PSL, another immunosuppressant, a weak negative correlation was observed between AUC 0-9 PSL40 and TL MPA . However, there was no correlation for other parameters. Steroids have been shown to enhance the activity of hepatic UGT, the primary enzyme for MPA metabolism. 35) In addition, in renal transplant patients, glucocorticoid dosing was found to correlate negatively with MPA AUC. 36) Therefore, PSL decreases plasma MPA level. However, based on this study, the contribution of PSL to MPA pharmacokinetics is small.
The plasma protein binding ratio of MPA was 98 to 99%, 27) and 82% bound to albumin 28) as described above. Therefore, MPA clearance is strongly influenced by change of protein binding ratio. It has been demonstrared that decreased MPA clearance accounts for increasing the serum protein-binding ratio because of increasing serum albumin levels with the recovery of renal function. 24, 28) In this study, increases of ALB level significantly decreased AUC MPA 0-9 and TL MPA , supporting the hypothesis about the time dependent decrease of MPA clearance with recovery of renal function. On the other hand, weak negative correlation was observed between T-Bil and AUC MPA 0-9 or TL MPA . In general, increase of T-Bil reflects a decrease of secretion of bile. Therefore, MPAG excretion into bile decreased, leading to a reduction of the EHRA of MPA, and the contribution to the AUC of reabsorbed MPA would be decreased. The result in this study that T-Bil level in the EHRA group was significantly lower than that in the non-EHRA group supported this consideration. This result also clinically supported the idea that CyA inhibits MPAG excretion into the bile, leading to MPAG accumulation in the plasma and a reduction of the EHRA of MPA.
It is generally agreed that there is poor correlation between TL MPA (12 h after MMF dosing) and AUC MPA 0-12 ; however, we determined that AUC MPA 0-9 correlated well with TL MPA (rϭ0.793-0.722) though the TL MPA in our institution was obtained at 15 h after MMF dosing. In this study, it was suggested that the EHRA has led to increasing interest in MMF medication. Secondary elevation of plasma MPA level was observed at 6-12 h after MMF dosing in our institution. Therefore, a variety of TL MPA (12 h after MMF dosing) may be caused by EHRA. Recently, limited sampling strategies for estimation of MPA AUC has been recommended 37, 38) because of poor correlation between TL MPA (12 h after MMF dosing) and AUC MPA 0-12 . However, TL MPA (15 h after MMF dosing) in our regimen may not require such strategies.
CONCLUSION
This study showed that MPA had highly variable pharmacokinetic behavior after MMF dosing in Japanease transplant patients. In addition, pharmacokinetic characteristics of MPA was influenced by the immunosuppressants such as CyA (reduction of EHRA of MPA) or FK (inhibition of the glucuronidation of MPA), but not influenced by PSL, and the contribution to the plasma level of MPA of FK might be smaller than that of CyA. On the other hand, the major toxic effect of MMF, gastrointestinal toxicity such as diarrhea, was related to the EHRA rather than the plasma MPA level. Therefore, it is considered that there may be a relationship between direct exposure of MPA to the intestinal epithelium and the development of intestinal toxicity. Moreover, the development of leukopenia was related to the EHRA rather than AUC MPA 0-9 , though the reason was unclear. These results suggest that a TDM for MPA after MMF dosing is useful in Japanease transplant patients. However, as an index of TDM, AUC obtained by multiple blood sampling after MMF dosing was desirable for estimating the EHRA. EHRA has led to increasing interest in MMF medication.
